Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Oragenics signed a Letter of Intent to exclusively license Sigyn Therapeutics' CardioDialysis technology for the treatment of Traumatic Brain Injury and other neurodegenerative diseases. The strategy aims to combine this blood purification approach with Oragenics' ONP-002 drug to target inflammation on both sides of the blood-brain barrier.
Key figures
- Royalty rate
- 3%
- Royalty term years
- 6
- Target closing days
- 90
- Shares issued for license
- 3250000
- Global tbi incidence annual
- 69 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.